8-K: Akero Therapeutics Announces Year-End 2023 Financial Results and Clinical Program Updates

Akero Therapeutics reported its fourth quarter and full year 2023 financial results, along with updates on its Phase 3 clinical program for efruxifermin (EFX) in MASH.

Summary

• Akero Therapeutics announced its financial results for the fourth quarter and full year ended December 31, 2023.
• The company has initiated two Phase 3 SYNCHRONY studies evaluating EFX for pre-cirrhotic MASH.
• A third Phase 3 SYNCHRONY study for cirrhotic MASH is expected to begin in the first half of 2024.
• The company reported a cash balance of $569.3 million at the end of 2023, which they believe will fund operations into 2026.
• Research and development expenses increased to $141.8 million for the year, up from $85.3 million in 2022.
• The company expects to report results from the second on-treatment biopsy in the Phase 2b HARMONY study in the first half of 2024.
• Preliminary results from the 96-week SYMMETRY study are expected in the first quarter of 2025.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the progress in Phase 3 trials and strong cash position, but tempered by the increased operating expenses and lack of statistical significance in the primary endpoint of the SYMMETRY study.

Positives

• The company has a strong cash position of $569.3 million, which is expected to fund operations into 2026.
• The initiation of two Phase 3 trials for EFX in pre-cirrhotic MASH is a significant step forward.
• The company observed statistically significant rates of MASH resolution in the Phase 2b SYMMETRY study at week 36.
• EFX was generally well-tolerated in clinical trials.
• The company is using a new pre-filled dual chamber syringe for EFX administration in Phase 3 trials, which is intended for commercial use.

Negatives

• The primary endpoint in the Phase 2b SYMMETRY study did not reach statistical significance, although a trend was observed.
• The company's operating expenses have increased significantly, with total operating expenses reaching $172.9 million for the year.

Risks

• The success of the ongoing and planned clinical trials is not guaranteed.
• Regulatory approvals for EFX are not assured.
• The company's ability to fund operations is dependent on its cash reserves and future financing.
• There are risks associated with the development and manufacturing of the new EFX formulation.
• The company may face challenges in enrolling patients in its Phase 3 studies.

Future Outlook

The company anticipates reporting results from the second on-treatment biopsy in the Phase 2b HARMONY study in the first half of 2024 and initiating the third Phase 3 SYNCHRONY study in the same period. Preliminary results from the 96-week SYMMETRY study are expected in the first quarter of 2025.

Management Comments

• Andrew Cheng, M.D., Ph.D., president and chief executive officer of Akero, stated that they concluded 2023 by dosing the first patients in their two Phase 3 SYNCHRONY studies.
• Management believes that the company's cash will be sufficient to fund its current operating plan into 2026.

Industry Context

The announcement is relevant to the broader pharmaceutical industry focused on developing treatments for metabolic diseases, particularly MASH, which has a high unmet medical need. The company's progress in Phase 3 trials positions it as a potential competitor in this space.

Comparison to Industry Standards

• Akero's focus on MASH aligns with the industry's growing attention to non-alcoholic fatty liver disease (NAFLD) and its more severe form, MASH.
• The company's Phase 3 program is comparable to other companies developing MASH treatments, such as Madrigal Pharmaceuticals with resmetirom, which has already achieved positive Phase 3 results.
• The use of a pre-filled dual chamber syringe for EFX administration is a move towards patient convenience, similar to trends in other injectable therapies.
• The reported cash balance of $569.3 million is substantial and positions Akero well compared to other clinical-stage biotech companies, allowing them to fund operations into 2026.

Stakeholder Impact

• Shareholders will be interested in the progress of the Phase 3 trials and the company's financial stability.
• Employees will be impacted by the company's growth and the expansion of its clinical programs.
• Patients with MASH stand to benefit from the potential approval of EFX.
• The company's suppliers and partners will be impacted by the increased manufacturing and clinical trial activities.

Next Steps

• The company will continue enrolling patients in the ongoing Phase 3 SYNCHRONY studies.
• The company plans to initiate the third Phase 3 SYNCHRONY study in the first half of 2024.
• The company will report results from the second on-treatment biopsy in the Phase 2b HARMONY study in the first half of 2024.
• The company will report preliminary results from the 96-week SYMMETRY study in the first quarter of 2025.

Key Dates

Keywords

Akero Therapeutics, Efruxifermin, MASH, MASLD, Clinical Trials, Phase 3, Liver Fibrosis, Metabolic Disease, Biotechnology, Drug Development